Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Active capsule Clear all

Conditions: Healthy
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COPD
Interventions: Curcumin therapy, Placebo, Standard care; Dietary Supplement · Other
Lead sponsor: Danbury Hospital; Other
Eligibility: 40 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Danbury, Connecticut

Conditions: Healthy Subjects
Interventions: PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend; Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 20 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Healthy Volunteers
Interventions: Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Soft Tissue Injury
Interventions: ibuprofen; Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 12 Years to 19 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
Interventions: NEM® brand eggshell membrane powder, curQ+® brand highly absorbable curcumin, EM Placebo, Curc Placebo, NEM® plus curQ+® combination; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Bipolar Disorder, Cocaine Dependence
Interventions: Citicoline, Placebo, Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hair Thinning
Interventions: Nutrafol Supplement capsules, Placebo capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Interventions: JAB-3312; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lupus Nephritis
Interventions: Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 28
States / cities: Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more

Conditions: Leukemia, Myeloid
Interventions: Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more

Conditions: Alopecia Areata
Interventions: PF-06651600, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more

Conditions: Hair Thinning
Interventions: Nutrafol® Men Hair Growth Nutraceutical, Placebo Supplement; Dietary Supplement · Other
Lead sponsor: Nutraceutical Wellness Inc.; Industry
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Manhattan Beach, California • San Diego, California

Conditions: Hypertriglyceridemia
Interventions: Lovaza (Omega-3 acid ethyl esters), Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Protein Metabolism
Interventions: Protease + Protein, Placebo + Protein; Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 20 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Glioma
Interventions: Lenvatinib, Bevacizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Chronic Stable Angina Pectoris
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Snoring
Interventions: SAS2094AH and SAS2094BH, SAS2094AL and SAS2094BL, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more

Conditions: Primary Membranous Nephropathy
Interventions: Povetacicept, Tacrolimus; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 24 more

Conditions: Dietary Carcinogenesis
Interventions: ACCS100, Placebo; Drug
Lead sponsor: Texas Enterosorbents Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity and Overweight
Interventions: Postbiotic, Placebo; Dietary Supplement
Lead sponsor: ResBiotic Nutrition, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Arterial Hypertension
Interventions: Cicletanine, Cicletanine Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Search by objective public record fields.

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Curcumin in Management of Chronic Obstructive Pulmonary Disease

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes

Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise

Citicoline for Bipolar 1 Disorder and Cocaine Dependence

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels

A Study in Subjects With Recurrent Malignant Glioma

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Pharmacological Intervention for Symptomatic Snoring

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"

A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)